Granules India Reports Strong Q1 FY27 Performance: Net Profit Jumps 59.8% YoY to ₹179.96 Crore

Hyderabad-based pharmaceutical manufacturing major Granules India Limited (CIN: L24110TG1991PLC012471) has announced its un-audited consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). Driven by steady growth in its core revenue from operations, the company posted a sharp 59.8% year-on-year (YoY) increase in net profit, demonstrating solid operating leverage and improved bottom-line performance.

Key Financial Highlights for Q1 FY27

Total Revenue from Operations: Stood at ₹1,476.77 crore (₹14,767.74 million) in Q1 FY27, registering a 22.0% YoY growth compared to ₹1,210.11 crore in Q1 FY26. Sale of products contributed ₹1,464.97 crore, with other operating revenue adding ₹11.80 crore. On a sequential basis, revenue remained virtually stable against ₹1,470.61 crore reported in Q4 FY26.

Total Income: Reached ₹1,479.04 crore (₹14,790.41 million) for the quarter, up 20.6% YoY from ₹1,226.45 crore in the corresponding quarter of the previous fiscal year. Other income for the period stood at ₹2.27 crore.

Profit Before Tax (PBT): Climbed 38.8% YoY to ₹240.40 crore (₹2,404.04 million) in Q1 FY27 from ₹173.19 crore (₹1,731.25 million, prior to exceptional items) in Q1 FY26. Sequentially, PBT saw a minor dip of 8.4% compared to ₹262.36 crore in Q4 FY26. No exceptional items were recorded during the quarter.

Net Profit (Profit After Tax): Surged 59.8% YoY to ₹179.96 crore (₹1,799.63 million) in Q1 FY27, up from ₹112.64 crore (₹1,126.36 million) in Q1 FY26. Sequentially, PAT moderated from ₹201.57 crore reported in Q4 FY26. Total tax expense for the quarter was ₹60.44 crore, comprising ₹46.58 crore in current tax and ₹13.86 crore in deferred tax.

Earnings Per Share (EPS): Basic and diluted EPS for Q1 FY27 stood at ₹7.26 per equity share (face value ₹1/- each), compared to ₹4.64 in Q1 FY26 and ₹8.23 in Q4 FY26.

Total Comprehensive Income

Total Comprehensive Income for the quarter came in at ₹210.02 crore (₹2,100.24 million), representing a 59.5% YoY rise over ₹131.66 crore in Q1 FY26. This includes net Other Comprehensive Income (OCI) of ₹30.06 crore, which was primarily driven by items that will be reclassified to profit or loss (net of tax).

Quarterly Expense Analysis

Total expenses for Q1 FY27 stood at ₹1,238.64 crore (₹12,386.37 million), compared to ₹1,056.02 crore in Q1 FY26 and ₹1,232.04 crore in Q4 FY26.

Cost of Materials Consumed: Stood at ₹495.84 crore (₹4,958.41 million).

Changes in Inventories: Impacted total costs by ₹11.98 crore (₹119.75 million).

Employee Benefits Expense: Increased to ₹254.57 crore (₹2,545.66 million) from ₹202.75 crore in Q1 FY26.

Other Expenses: Totaled ₹375.48 crore (₹3,754.84 million), compared to ₹335.51 crore in Q1 FY26.

Depreciation & Amortisation: Amounted to ₹79.65 crore (₹796.49 million), compared to ₹68.85 crore in Q1 FY26.

Finance Costs: Reduced sequentially to ₹21.12 crore (₹211.22 million) from ₹32.69 crore in Q4 FY26 and ₹23.78 crore in Q1 FY26.

Granules India's paid-up equity share capital remained steady at ₹24.78 crore (₹247.80 million), consisting of equity shares with a face value of ₹1/- each. Other equity (excluding capital) as of the balance sheet date stood at ₹5,060.22 crore (₹50,602.15 million).

Shares of Granules India Limited was last trading in BSE at Rs. 875.95 as compared to the previous close of Rs. 880.10. The total number of shares traded during the day was 37187 in over 1130 trades.

The stock hit an intraday high of Rs. 900.75 and intraday low of 872.50. The net turnover during the day was Rs. 32807831.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate